Despite the coronavirus pandemic’s inspection hiatus, the US Food and Drug Administration’s field organization, the Office of Regulatory Affairs, has been able to make judgments on the quality of hundreds of drug manufacturing facilities without visiting them.
That finding, delivered by FDA assistant commissioner Elizabeth Miller at this year’s virtual Parenteral Drug Association/FDA conference, provides some degree of assurance to pharmaceutical companies that many expected approvals will not